AUSTIN, Texas, Feb. 12, 2026 — IntraBio announced positive topline results from its pivotal Phase III IB1001-303 clinical trial evaluating levacetylleucine (N-acetyl-L-leucine) for the treatment of Ataxia-Telangiectasia (A-T), achieving the primary endpoint and multiple secondary endpoints with high statistical significance, while demonstrating favorable safety and tolerability in both pediatric and adult patients with the rare neurodegenerative disorder.
Science Significance
The Phase III study marks a major scientific milestone for rare neurology therapeutics. Levacetylleucine produced a statistically significant −1.88 improvement in SARA scores versus placebo after 12 weeks, reflecting clinically meaningful gains in motor coordination and neurological function. Secondary endpoints reinforced efficacy, including improvements on the International Cooperative Ataxia Rating Scale (ICARS) and Clinical Global Impression of Improvement (CGI-I) assessments. These findings validate leucine-based metabolic modulation as a therapeutic strategy in cerebellar neurodegeneration. The crossover, randomized, double-blind design strengthens clinical credibility, while long-term extension phases are expected to further define durability of response. Collectively, the data position levacetylleucine as one of the most advanced investigational therapies targeting the neurological manifestations of A-T.
Regulatory Significance
Following the positive readout, IntraBio confirmed plans for immediate regulatory submissions to the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global authorities. Given the absence of approved A-T treatments, the therapy may qualify for expedited regulatory pathways, including orphan and rare disease review incentives. Regulatory filings will rely on pivotal efficacy data, safety outcomes, and crossover trial design robustness. Levacetylleucine already has regulatory precedent, being approved in the United States for neurological manifestations of Niemann-Pick disease type C, which may support regulatory familiarity regarding pharmacology and safety. If approved, the therapy could become the first authorized treatment specifically indicated for Ataxia-Telangiectasia.
Business Significance
Advertisement
From a commercial perspective, the trial success significantly strengthens IntraBio’s rare disease portfolio. A-T represents a high-unmet-need orphan market with limited competition and strong pricing potential under rare disease reimbursement frameworks. Positive Phase III results de-risk late-stage development while enhancing investor confidence, partnership attractiveness, and lifecycle expansion opportunities. The company is concurrently advancing levacetylleucine in other neurological and mitochondrial disorders, including CACNA1A-related conditions, creating pipeline synergies around a single metabolic therapy platform. Regulatory filings across multiple geographies also signal preparation for global commercialization strategy and market access planning.
Patients’ Significance
For patients and families, the findings represent a transformative development. Ataxia-Telangiectasia is a progressive, inherited neurodegenerative disease characterized by cerebellar degeneration, loss of coordination, immune dysfunction, and increased cancer risk. Symptoms often begin in early childhood and worsen over time, frequently leading to wheelchair dependence and life-threatening complications. With no approved therapies currently available, treatment has been limited to supportive care. Levacetylleucine’s demonstrated improvements in neurological symptoms, motor function, and daily activity performance offer the potential to meaningfully slow functional decline and improve quality of life for both pediatric and adult populations.
Policy Significance
The development highlights the importance of rare disease policy frameworks in advancing therapies for ultra-low-prevalence disorders affecting approximately 1 in 70,000 individuals. Incentive structures—including orphan designation, regulatory fee reductions, and market exclusivity—play a central role in enabling biotech investment in conditions lacking commercial scale. Successful Phase III outcomes in A-T also reinforce the value of patient-organization collaboration, adaptive trial design, and crossover methodologies in rare disease research where patient populations are limited. As regulators evaluate submissions, the case may further shape evidentiary standards for neurological orphan drug approvals.
With pivotal efficacy achieved, regulatory filings imminent, and safety outcomes aligned with prior clinical experience, levacetylleucine advances toward becoming the first disease-targeted therapy for Ataxia-Telangiectasia. The program reflects the convergence of rare disease science, regulatory acceleration pathways, and precision metabolic therapeutics, offering renewed hope for patients facing a devastating neurodegenerative condition while reinforcing the growing momentum of orphan neurology drug development.
Source: IntraBio Corporate press release
